Which funds bought or sold IDXX in Q3 2026?
Idexx Labs Inc. 4 funds bought, 5 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$57M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- T. Rowe Price+$539M
- Arrowstreet+$153M
- Holocene+$83M
- GlenviewNEW+$627K
- Wellington−$294M
- Fundsmith−$159M
- Polen−$73M
- Baillie Gifford−$33M
- FarallonOUT−$5M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (4)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| T. Rowe Price Asset manager | Added+46629.6% | +$539M | $540M |
| Arrowstreet Quant & multi-strategy | Added+27.4% | +$153M | $710M |
| Holocene Hedge fund | Added+90.2% | +$83M | $174M |
| Glenview Hedge fund | New | +$627K | $627K |
Sold (5)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Wellington Asset manager | Trimmed-77.6% | −$294M | $85M |
| Fundsmith Value investor | Trimmed-29.9% | −$159M | $373M |
| Polen Growth / crossover | Trimmed-26.3% | −$73M | $205M |
| Baillie Gifford Growth / crossover | Trimmed-18% | −$33M | $152M |
| Farallon Hedge fund | Sold out | −$5M | — |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.